More about

Metastatic Urothelial Carcinoma

News
March 07, 2024
1 min read
Save

FDA approves Opdivo plus chemotherapy for unresectable or metastatic urothelial carcinoma

FDA approves Opdivo plus chemotherapy for unresectable or metastatic urothelial carcinoma

The FDA approved nivolumab in combination with cisplatin and gemcitabine for the first-line treatment of adults with unresectable or metastatic urothelial carcinoma, according to a press release.

News
January 02, 2024
10 min read
Save

‘Monumental’ and ‘highly meaningful’ advances across solid tumors highlight ESMO program

‘Monumental’ and ‘highly meaningful’ advances across solid tumors highlight ESMO program

MADRID — Remarkable. Highly meaningful. Monumental.

News
July 11, 2023
1 min read
Save

Immunotherapy-chemotherapy combination extends survival in metastatic urothelial carcinoma

Immunotherapy-chemotherapy combination extends survival in metastatic urothelial carcinoma

The addition of nivolumab to cisplatin-based chemotherapy improved outcomes compared with standard regimens for certain patients with advanced urothelial carcinoma, according to the agent’s manufacturer.

News
March 10, 2023
3 min read
Save

Atezolizumab may benefit some patients with metastatic urothelial carcinoma, high PD-L1 expression

Atezolizumab may benefit some patients with metastatic urothelial carcinoma, high PD-L1 expression

SAN FRANCISCO — Atezolizumab monotherapy improved OS compared with chemotherapy among patients with PD-L1-high, cisplatin-ineligible metastatic urothelial carcinoma, according to an exploratory analysis of a randomized phase 3 study.

News
February 21, 2023
3 min read
Save

Findings from negative urothelial carcinoma trial suggest ‘chemotherapy backbone matters’

Findings from negative urothelial carcinoma trial suggest ‘chemotherapy backbone matters’

SAN FRANCISCO — The addition of atezolizumab to platinum-based chemotherapy failed to significantly improve survival for patients with metastatic urothelial carcinoma, according to a final analysis of the randomized phase 3 IMvigor130 trial.

News
July 09, 2021
2 min read
Save

FDA approves enfortumab vedotin for locally advanced, metastatic urothelial carcinoma

The FDA today granted approval to enfortumab vedotin-ejfv for treatment of adults with locally advanced or metastatic urothelial cancer.

News
July 14, 2020
4 min read
Save

Atezolizumab plus chemotherapy improves PFS in metastatic urothelial carcinoma

Atezolizumab plus chemotherapy improves PFS in metastatic urothelial carcinoma

Atezolizumab plus platinum-based chemotherapy prolonged PFS as first-line therapy for patients with metastatic urothelial carcinoma, according to results of the randomized phase 3 IMvigor130 trial published in The Lancet.

News
July 01, 2020
1 min read
Save

FDA approves Bavencio for first-line maintenance of advanced bladder cancer

FDA approves Bavencio for first-line maintenance of advanced bladder cancer

The FDA approved avelumab for the first-line maintenance treatment of locally advanced or metastatic urothelial carcinoma, according to a press release from the manufacturer.

News
March 10, 2020
2 min read
Save

Enfortumab vedotin plus pembrolizumab induces durable responses in metastatic urothelial carcinoma

Enfortumab vedotin plus pembrolizumab induces durable responses in metastatic urothelial carcinoma

The combination of enfortumab vedotin and pembrolizumab conferred high rates of durable responses among cisplatin-ineligible patients with metastatic urothelial carcinoma, according to results of the multicohort EV-103 study.

News
January 12, 2020
1 min read
Save

Avelumab maintenance extends OS in advanced urothelial carcinoma

Avelumab maintenance extends OS in advanced urothelial carcinoma

The addition of maintenance avelumab to best supportive care extended OS for patients with previously untreated locally advanced or metastatic urothelial carcinoma, according to study results released by the agent’s manufacturer.

View more